- Home
- IMRX vs AVTX Comparison
IMRX vs AVTX Comparison
Compare IMRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- AVTX
- Stock Information
- Founded
- IMRX 2008
- AVTX 2011
- Country
- IMRX United States
- AVTX United States
- Employees
- IMRX N/A
- AVTX N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- AVTX Health Care
- Exchange
- IMRX Nasdaq
- AVTX Nasdaq
- Market Cap
- IMRX 68.4M
- AVTX 57.4M
- IPO Year
- IMRX 2021
- AVTX 2015
- Fundamental
- Price
- IMRX $2.60
- AVTX $4.73
- Analyst Decision
- IMRX Strong Buy
- AVTX Strong Buy
- Analyst Count
- IMRX 4
- AVTX 7
- Target Price
- IMRX $13.25
- AVTX $31.00
- AVG Volume (30 Days)
- IMRX 2.4M
- AVTX 89.2K
- Earning Date
- IMRX 08-05-2025
- AVTX 08-11-2025
- Dividend Yield
- IMRX N/A
- AVTX N/A
- EPS Growth
- IMRX N/A
- AVTX N/A
- EPS
- IMRX N/A
- AVTX N/A
- Revenue
- IMRX N/A
- AVTX $441,000.00
- Revenue This Year
- IMRX N/A
- AVTX N/A
- Revenue Next Year
- IMRX N/A
- AVTX N/A
- P/E Ratio
- IMRX N/A
- AVTX $0.69
- Revenue Growth
- IMRX N/A
- AVTX N/A
- 52 Week Low
- IMRX $1.00
- AVTX $3.39
- 52 Week High
- IMRX $3.83
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- IMRX 70.10
- AVTX 57.87
- Support Level
- IMRX $1.66
- AVTX $4.46
- Resistance Level
- IMRX $2.24
- AVTX $4.90
- Average True Range (ATR)
- IMRX 0.32
- AVTX 0.37
- MACD
- IMRX 0.07
- AVTX 0.09
- Stochastic Oscillator
- IMRX 89.51
- AVTX 88.61
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).